Scarica l'app Stockscreener
186.11
0.26%
0.49
Dopo l'orario di chiusura:
186.11
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie Inc. (ABBV) and Chicago Cubs Launch “Striking Out Cancer” Campaign - Insider Monkey
AbbVie announces multi-year partnership with the Chicago Cubs - TipRanks
AbbVie (ABBV) Gains As Market Dips: What You Should Know - Yahoo Finance
Final Trades: JPMorgan, Meta, Abbvie and Gap - CNBC
AbbVie Partners with Chicago Cubs on "Striking Out Cancer" | ABB - GuruFocus
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV)June 3, 2025 Deadline to Join – Contact Levi & Korsinsky - TradingView
AbbVie’s ADC win shows how pharma can break through in solid tumors - Pharma Voice
AbbVie (ABBV) Stock Dips in Morning Trade: What Key Numbers Reveal - Daily Chhattisgarh News
Analyst recommendations: AbbVie, Emerson Electric, Marriott International, Zscaler, and Monster Beverage… - marketscreener.com
AbbVie (ABBV) Partners with Chicago Cubs for Cancer Awareness In - GuruFocus
AbbVie (ABBV) Partners with Chicago Cubs for Cancer Awareness Initiative | ABBV Stock News - GuruFocus
AbbVie Partners with Chicago Cubs on "Striking Out Cancer" - PR Newswire
How Is AbbVie's Stock Performance Compared To Other Pharmaceuticals Stocks? - Barchart.com
Berenberg Adjusts Price Target on AbbVie to $170 From $195, Maintains Hold Rating - marketscreener.com
The Zacks Analyst Blog Highlights Berkshire Hathaway, AbbVie, Intuitive Surgical, Hamilton Beach Brands and AXIL Brands - Yahoo Finance
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. LawsuitABBV - marketscreener.com
Top Research Reports for Berkshire Hathaway, AbbVie & Intuitive Surgical - MSN
Contact The Gross Law Firm by June 3, 2025 Deadline to Join Class Action Against Cerevel Therapeutics Holdings, Inc.(ABBV) - TradingView
AbbVie Stock Down Around 13% in 3 Months: Time to Buy the Dip? - Yahoo Finance
AbbVie: Fairly Valued, But Lacking A Spark - Seeking Alpha
Cancer Therapeutics Market Is Booming So Rapidly 2025-2032 - openPR.com
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for InvestorsContact The Gross Law Firm - marketscreener.com
Drug Device Combination Products Market Analysis Report 2025-2030: Discover the Latest Advances and Opportunities - GlobeNewswire Inc.
AbbVie Inc. (ABBV)’s Pipeline Advances with Temab-A and ABBV-706, Shares Flat - Yahoo Finance
Sarah Cannon Research Institute Announces Strategic Alliance with AbbVie to Advance Novel Cancer Therapies - marketscreener.com
CERE DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - GlobeNewswire Inc.
AbbVie (NYSE:ABBV) Showcases Promising Phase 1 ADC Results For Advanced Cancers - Yahoo Finance
Bearish Sentiment and Increased Put Activity for AbbVie (ABBV) | - GuruFocus
AbbVie put volume heavy and directionally bearish - TipRanks
Sarah Cannon Research Institute Announces Strategic Alliance With AbbVie to Advance Novel Cancer Therapies - BioSpace
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? - sharewise
Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - GlobeNewswire
AbbVie’s Allergan cuts over 200 staff after botched marketing campaign - PharmaLive
AbbVie’s Allergan Cuts Over 200 Staff After Botched Marketing Campaign - BioSpace
AbbVie Inc. (ABBV) Scores Major Legal Victory as Illinois Court Shuts Down $63 Billion Allergan Shareholder Lawsuit - MSN
AbbVie To Present Cancer Trial Data At Upcoming ASCO Event - Benzinga
AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio - Investing News Network
AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio | ABBV Stock News - GuruFocus
Tissue Engineering Market Generated Opportunities, Future - openPR.com
Prurigo Nodularis Market - GlobeNewswire Inc.
AbbVie’s SWOT analysis: biopharma giant faces pipeline challenges amid stock growth - Investing.com
Precision immunology Market Growth in Future Scope 2025-2032 | - openPR.com
Immunomodulatory Drugs Market in 2025 Detailed Study Analysis | - openPR.com
Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie - insights.citeline.com
CERE DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - GlobeNewswire Inc.
AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer - MSN
Key Drivers Behind AbbVie’s (ABBV) Performance - Insider Monkey
Levi & Korsinsky Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineABBV - marketscreener.com
AbbVie (NYSE:ABBV) Faces Legal Scrutiny Over Merger With Cerevel - Yahoo Finance
AbbVie and U of T Mississauga's SpinUp Announce Neuropeutics Inc as First AbbVie Biotech Innovators Award Recipient - Investing News Network
AbbVie Secures Legal Victory Over Allergan Share Dispute - USA Herald
1.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):